ANTX
HealthcareAN2 Therapeutics, Inc.
$5.18-0.26 (-4.78%)
Prev Close
$5.44
Open
$5.43
High
$5.47
Low
$4.78
Volume
517.7K
Market Cap
$143.9M
P/E
—
Div Yield
—
Over the past 12 months, insider activity at AN2 Therapeutics, Inc. (ANTX) has been dominated by selling, with 2 insider purchases totaling $20.8K and 13 insider sales totaling $3.19M. The most recent insider transaction was by Williams Sarah Joanne (officer: Principal Accounting Officer), who sold $346.62 worth of shares on Mar 5, 2026. AN2 Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $143.9M.
Buys (12M)
2
$20.8K
Sells (12M)
13
$3.19M
Net Activity
Net Seller
$3.17M
Active Insiders
8
last 12 mo
ANTX Price Chart
ANTX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 5, 2026↗ | Williams Sarah Joanne | officer: Principal Accounting Officer | Sell | 327 | $1.06 | $346.62 | 66,848 |
| Jan 7, 2026↗ | Chanda Sanjay | officer: Chief Development Officer | Sell | 9,251 | $1.01 | $9.3K | 81,779 |
| Jan 7, 2026↗ | Day Lucy | officer: Chief Financial Officer | Sell | 8,807 | $1.01 | $8.9K | 80,875 |
| Jan 7, 2026↗ | Eizen Joshua M | officer: See Remarks | Sell | 24,854 | $1.00 | $25.0K | 159,430 |
| Jan 7, 2026↗ | Prior Stephen David | officer: Chief Strategy Officer | Sell | 6,462 | $1.01 | $6.5K | 61,944 |
| Jan 5, 2026↗ | Chanda Sanjay | Chief Development Officer | Sell | 9,251 | $1.01 | $9.3K | 0 |
| Jan 5, 2026↗ | Day Lucy | Chief Financial Officer | Sell | 8,807 | $1.01 | $8.9K | 0 |
| Jan 5, 2026↗ | Eizen Joshua M | See Remarks | Sell | 24,854 | $1.00 | $25.0K | 0 |
| Jan 5, 2026↗ | Prior Stephen David | Chief Strategy Officer | Sell | 6,462 | $1.01 | $6.5K | 0 |
| Nov 4, 2025↗ | Eizen Joshua M | See Remarks | Sell | 2,819 | $1.14 | $3.2K | 0 |
| Nov 4, 2025↗ | Prior Stephen David | Chief Strategy Officer | Sell | 765 | $1.14 | $872.10 | 0 |
| Jun 12, 2025↗ | Leonard Braden Michael | 10% Owner | Sell | 200,000 | $1.09 | $218.0K | 0 |
| Jun 2, 2025↗ | Easom Eric | Chief Executive Officer | Buy | 10,000 | $1.07 | $10.7K | 0 |
| May 28, 2025↗ | FitzPatrick Margaret M | Director | Buy | 8,610 | $1.18 | $10.1K | 0 |
| May 28, 2025↗ | Leonard Braden Michael | 10% Owner | Sell | 2,532,000 | $1.13 | $2.87M | 0 |
| Jan 3, 2025↗ | Chanda Sanjay | Chief Development Officer | Sell | 2,957 | $1.34 | $4.0K | 0 |
| Jan 3, 2025↗ | Day Lucy | Chief Financial Officer | Sell | 2,957 | $1.34 | $4.0K | 0 |
| Jan 3, 2025↗ | Eizen Joshua M | See Remarks | Sell | 9,663 | $1.34 | $13.0K | 0 |
| Jan 3, 2025↗ | Prior Stephen David | Chief Strategy Officer | Sell | 2,029 | $1.34 | $2.7K | 0 |
| Dec 6, 2024↗ | Readnour Robin Shane | Director | Buy | 60,000 | $1.45 | $86.7K | 0 |
| Nov 27, 2024↗ | Zakrzewski Joseph S | Director | Buy | 2,000 | $1.40 | $2.8K | 0 |
| Nov 26, 2024↗ | Readnour Robin Shane | Director | Buy | 75,000 | $1.41 | $105.7K | 0 |
| Nov 19, 2024↗ | Readnour Robin Shane | Director | Buy | 200,000 | $1.07 | $213.1K | 0 |
| Nov 18, 2024↗ | Easom Eric | Chief Executive Officer | Buy | 50,000 | $1.00 | $50.0K | 0 |
| Nov 18, 2024↗ | Zakrzewski Joseph S | Director | Buy | 25,000 | $1.00 | $25.0K | 0 |
| Aug 14, 2024↗ | Leonard Braden Michael | 10% Owner | Buy | 1,500,000 | $1.04 | $1.56M | 0 |
| Jan 18, 2024↗ | Zakrzewski Joseph S | Director | Sell | 100,000 | $19.11 | $1.91M | 0 |
| Jan 16, 2024↗ | Aziz Kabeer | Director | Sell | 100,000 | $19.65 | $1.97M | 0 |
| Jan 12, 2024↗ | Readnour Robin Shane | Director | Sell | 1,425 | $21.91 | $31.2K | 0 |
| Jan 10, 2024↗ | Readnour Robin Shane | Director | Sell | 3,669 | $21.93 | $80.4K | 0 |
| Jan 9, 2024↗ | Krause Kevin Michael | Chief Strategy Officer | Sell | 7,417 | $20.14 | $149.4K | 0 |
| Jan 2, 2024↗ | Easom Eric | Chief Executive Officer | Sell | 2,777 | $20.09 | $55.8K | 0 |
| Jan 2, 2024↗ | Krause Kevin Michael | Chief Strategy Officer | Sell | 2,583 | $20.12 | $52.0K | 0 |
| Nov 14, 2023↗ | Aziz Kabeer | Director | Sell | 1,810 | $16.15 | $29.2K | 0 |
| Sep 29, 2023↗ | Aziz Kabeer | Director | Sell | 104,773 | $16.27 | $1.70M | 0 |
| Sep 27, 2023↗ | Aziz Kabeer | Director | Sell | 9,357 | $16.11 | $150.7K | 0 |
| Aug 23, 2023↗ | Aziz Kabeer | Director | Sell | 7,940 | $16.03 | $127.3K | 0 |
| May 15, 2023↗ | Easom Eric | Chief Executive Officer | Buy | 10,000 | $5.38 | $53.8K | 0 |
| Nov 10, 2022↗ | Easom Eric | Chief Executive Officer | Sell | 4,436 | $15.32 | $68.0K | 0 |
| Nov 8, 2022↗ | Easom Eric | Chief Executive Officer | Sell | 17,166 | $15.60 | $267.8K | 0 |
| Nov 3, 2022↗ | Easom Eric | Chief Executive Officer | Sell | 35,196 | $15.86 | $558.3K | 0 |
| Oct 31, 2022↗ | Easom Eric | Chief Executive Officer | Sell | 4,232 | $15.27 | $64.6K | 0 |
| Oct 27, 2022↗ | Easom Eric | Chief Executive Officer | Sell | 2,607 | $15.18 | $39.6K | 0 |
| Oct 24, 2022↗ | Easom Eric | Chief Executive Officer | Sell | 9,350 | $15.76 | $147.4K | 0 |
| Oct 20, 2022↗ | Easom Eric | Chief Executive Officer | Sell | 21,244 | $16.47 | $349.9K | 0 |
| Mar 29, 2022↗ | Aziz Kabeer | Director | Buy | 166,666 | $15.00 | $2.50M | 0 |
| Mar 29, 2022↗ | Readnour Robin Shane | Director | Buy | 153,334 | $15.00 | $2.30M | 0 |
ANTX Insider Buying Activity
The following table shows recent insider purchases of AN2 Therapeutics, Inc. (ANTX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 2, 2025↗ | Easom Eric | Chief Executive Officer | Buy | 10,000 | $1.07 | $10.7K | 0 |
| May 28, 2025↗ | FitzPatrick Margaret M | Director | Buy | 8,610 | $1.18 | $10.1K | 0 |
| Dec 6, 2024↗ | Readnour Robin Shane | Director | Buy | 60,000 | $1.45 | $86.7K | 0 |
| Nov 27, 2024↗ | Zakrzewski Joseph S | Director | Buy | 2,000 | $1.40 | $2.8K | 0 |
| Nov 26, 2024↗ | Readnour Robin Shane | Director | Buy | 75,000 | $1.41 | $105.7K | 0 |
| Nov 19, 2024↗ | Readnour Robin Shane | Director | Buy | 200,000 | $1.07 | $213.1K | 0 |
| Nov 18, 2024↗ | Easom Eric | Chief Executive Officer | Buy | 50,000 | $1.00 | $50.0K | 0 |
| Nov 18, 2024↗ | Zakrzewski Joseph S | Director | Buy | 25,000 | $1.00 | $25.0K | 0 |
| Aug 14, 2024↗ | Leonard Braden Michael | 10% Owner | Buy | 1,500,000 | $1.04 | $1.56M | 0 |
| May 15, 2023↗ | Easom Eric | Chief Executive Officer | Buy | 10,000 | $5.38 | $53.8K | 0 |
| Mar 29, 2022↗ | Aziz Kabeer | Director | Buy | 166,666 | $15.00 | $2.50M | 0 |
| Mar 29, 2022↗ | Readnour Robin Shane | Director | Buy | 153,334 | $15.00 | $2.30M | 0 |
ANTX Insider Selling Activity
The following table shows recent insider sales of AN2 Therapeutics, Inc. (ANTX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 5, 2026↗ | Williams Sarah Joanne | officer: Principal Accounting Officer | Sell | 327 | $1.06 | $346.62 | 66,848 |
| Jan 7, 2026↗ | Chanda Sanjay | officer: Chief Development Officer | Sell | 9,251 | $1.01 | $9.3K | 81,779 |
| Jan 7, 2026↗ | Day Lucy | officer: Chief Financial Officer | Sell | 8,807 | $1.01 | $8.9K | 80,875 |
| Jan 7, 2026↗ | Eizen Joshua M | officer: See Remarks | Sell | 24,854 | $1.00 | $25.0K | 159,430 |
| Jan 7, 2026↗ | Prior Stephen David | officer: Chief Strategy Officer | Sell | 6,462 | $1.01 | $6.5K | 61,944 |
| Jan 5, 2026↗ | Chanda Sanjay | Chief Development Officer | Sell | 9,251 | $1.01 | $9.3K | 0 |
| Jan 5, 2026↗ | Day Lucy | Chief Financial Officer | Sell | 8,807 | $1.01 | $8.9K | 0 |
| Jan 5, 2026↗ | Eizen Joshua M | See Remarks | Sell | 24,854 | $1.00 | $25.0K | 0 |
| Jan 5, 2026↗ | Prior Stephen David | Chief Strategy Officer | Sell | 6,462 | $1.01 | $6.5K | 0 |
| Nov 4, 2025↗ | Eizen Joshua M | See Remarks | Sell | 2,819 | $1.14 | $3.2K | 0 |
| Nov 4, 2025↗ | Prior Stephen David | Chief Strategy Officer | Sell | 765 | $1.14 | $872.10 | 0 |
| Jun 12, 2025↗ | Leonard Braden Michael | 10% Owner | Sell | 200,000 | $1.09 | $218.0K | 0 |
| May 28, 2025↗ | Leonard Braden Michael | 10% Owner | Sell | 2,532,000 | $1.13 | $2.87M | 0 |
| Jan 3, 2025↗ | Chanda Sanjay | Chief Development Officer | Sell | 2,957 | $1.34 | $4.0K | 0 |
| Jan 3, 2025↗ | Day Lucy | Chief Financial Officer | Sell | 2,957 | $1.34 | $4.0K | 0 |
| Jan 3, 2025↗ | Eizen Joshua M | See Remarks | Sell | 9,663 | $1.34 | $13.0K | 0 |
| Jan 3, 2025↗ | Prior Stephen David | Chief Strategy Officer | Sell | 2,029 | $1.34 | $2.7K | 0 |
| Jan 18, 2024↗ | Zakrzewski Joseph S | Director | Sell | 100,000 | $19.11 | $1.91M | 0 |
| Jan 16, 2024↗ | Aziz Kabeer | Director | Sell | 100,000 | $19.65 | $1.97M | 0 |
| Jan 12, 2024↗ | Readnour Robin Shane | Director | Sell | 1,425 | $21.91 | $31.2K | 0 |
| Jan 10, 2024↗ | Readnour Robin Shane | Director | Sell | 3,669 | $21.93 | $80.4K | 0 |
| Jan 9, 2024↗ | Krause Kevin Michael | Chief Strategy Officer | Sell | 7,417 | $20.14 | $149.4K | 0 |
| Jan 2, 2024↗ | Easom Eric | Chief Executive Officer | Sell | 2,777 | $20.09 | $55.8K | 0 |
| Jan 2, 2024↗ | Krause Kevin Michael | Chief Strategy Officer | Sell | 2,583 | $20.12 | $52.0K | 0 |
| Nov 14, 2023↗ | Aziz Kabeer | Director | Sell | 1,810 | $16.15 | $29.2K | 0 |
| Sep 29, 2023↗ | Aziz Kabeer | Director | Sell | 104,773 | $16.27 | $1.70M | 0 |
| Sep 27, 2023↗ | Aziz Kabeer | Director | Sell | 9,357 | $16.11 | $150.7K | 0 |
| Aug 23, 2023↗ | Aziz Kabeer | Director | Sell | 7,940 | $16.03 | $127.3K | 0 |
| Nov 10, 2022↗ | Easom Eric | Chief Executive Officer | Sell | 4,436 | $15.32 | $68.0K | 0 |
| Nov 8, 2022↗ | Easom Eric | Chief Executive Officer | Sell | 17,166 | $15.60 | $267.8K | 0 |
| Nov 3, 2022↗ | Easom Eric | Chief Executive Officer | Sell | 35,196 | $15.86 | $558.3K | 0 |
| Oct 31, 2022↗ | Easom Eric | Chief Executive Officer | Sell | 4,232 | $15.27 | $64.6K | 0 |
| Oct 27, 2022↗ | Easom Eric | Chief Executive Officer | Sell | 2,607 | $15.18 | $39.6K | 0 |
| Oct 24, 2022↗ | Easom Eric | Chief Executive Officer | Sell | 9,350 | $15.76 | $147.4K | 0 |
| Oct 20, 2022↗ | Easom Eric | Chief Executive Officer | Sell | 21,244 | $16.47 | $349.9K | 0 |
ANTX Insiders
Similar Stocks to ANTX
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$536.12+0.97%
$23.50B
MRNA
Moderna, Inc.
$52.56-1.89%
$20.76B
ROIV
Roivant Sciences Ltd.
$28.06-1.44%
$20.08B
RPRX
Royalty Pharma plc
$45.65-0.57%
$19.56B